



## **Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference**

June 5, 2024

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45<sup>th</sup> Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET.

The presentation will be webcast live and may be accessed [here](#) or by visiting Madrigal's website's Investor Relations Events [page](#). A replay of the webcast will be available after the event.

### **About Madrigal Pharmaceuticals**

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR- $\beta$  agonist designed to target key underlying causes of NASH. For more information, visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

### **Investor Contact**

Tina Ventura, Madrigal Pharmaceuticals, Inc., [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

### **Media Contact**

Christopher Frates, Madrigal Pharmaceuticals, Inc., [media@madrigalpharma.com](mailto:media@madrigalpharma.com)



Source: Madrigal Pharmaceuticals, Inc.